UNSPSC 51151545: Pilocarpine monohydrochloride

This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0WW6D218XJ, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, monohydrochloride, (3s,4r)-, but more generally known as pilocarpine monohydrochloride, which bears US NIH Compound Identifier 4819.

European Medicines Agency schedules pilocarpine monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03818MIG. Most nations, for tariff purposes, schedule pilocarpine monohydrochloride under HS 29399990. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.CL.

UNSPSC 51151545 Pilocarpine monohydrochloride is a Commodity code that in practice encompasses pharmaceutical products and drug-delivery systems procured by state and local health agencies, though recent solicitations show significant scope mismatch — the opportunities tagged under this code involve naloxone (an opioid antagonist) and drug deactivation systems, not pilocarpine eye drops. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county health building, while the Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor input on direct-to-manufacturer prescription fulfillment models. The issuing bodies soliciting under this code span county health agencies and state health departments pursuing competitive bidding and exploratory information-gathering on pharmaceutical procurement and delivery logistics.

Geographic activity centers on Florida and Texas based on recent postings. The Seminole County opportunity (IFB, response due July 26, 2023) requires electronic bid submission through the county's e-Procurement Portal, unit pricing for each line item, drug-free workplace certification, E-Verify compliance, and standard insurance coverage; the contract carries a two-year initial term with a one-year renewal option and a three-month probationary termination clause, with potential FEMA funding bringing additional federal compliance obligations including the Clean Air Act and Federal Water Pollution Control Act. The Texas HHS RFI (response due April 3, 2026) solicited vendor capabilities for direct contracting with self-insured employers and state agencies outside traditional pharmacy benefit manager and group purchasing organization channels, requesting experience with negotiated net pricing models and value-based arrangements. Neither opportunity specifies set-aside designations or budget ranges; the code shows limited recent activity and the opportunities cited do not align with the pilocarpine monograph, signaling either miscoding in the state procurement system or infrequent purchasing activity under this specific pharmaceutical commodity.